Skip to main content

Table 1 Clinical and demographic features of study population, and comparison between MIDASRes / NON-MIDASRes and MMDRes / NON-MMDRes groups

From: Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial

  Total MIDASRes NON-MIDASRes p-value MMDRes NON-MMDRes p-value
n 77 43 34 - 42 35 -
Age, (years, m ± sd) 49.8 ± 9.5 50.3 ± 9.1 49.2 ± 10.0 0.597 50.0 ± 9.1 49.2 ± 10.0 0.967
Females, n (%) 55 (71.4) 32 (74.4) 23 (67.6) 0.614 31 (73.8) 24 (68.6) 0.623
Age at headache onset (years, m ± sd) 14.5 ± 6.9 13.2 ± 5.5 16.2 ± 8.1 0.104 15.2 ± 7.3 16.2 ± 8.1 0.300
Years lived with migraine (years, m ± sd) 35.6 ± 10.8 37.1 ± 9.6 33.6 ± 11.9 0.177 35.3 ± 11.0 33.6 ± 11.9 0.701
Years lived with chronic migraine (years, m ± sd) 13.1 ± 10.3 13.7 ± 10.3 12.4 ± 10.3 0.495 12.0 ± 9.3 12.4 ± 10.3 0.424
Migraine with aura, n (%) 13 (16.9) 6 (14.0) 7 (20.6) 0.545 8 (19.0) 5 (14.3) 0.762
MOH, n (%) 71 (92.2) 41 (95.3) 30 (88.2) 0.397 39 (92.9) 32 (91.4) 0.654
Previous detoxification for MOH, n (%) 69 (89.6) 40 (93.0) 29 (85.3)   38 (90.5) 32 (91.4) 0.652
Preventive treatment
 Patients on preventive treatment at T0, n (%) 42 (54.5) 18 (41.9) 24 (70.6) 0.021 24 (57.1) 18 (51.4) 0.652
 Number of previously failed preventive treatments (m ± sd) 3.8 ± 1.2 4.0 ± 1.3 3.6 ± 1.5 0.199 3.8 ± 1.6 4.1 ± 0.98 0.439
 Previous BoNT-A treatment, n (%) 47 (61.0) 27 (62.8) 20 (58.8) 0.815 24 (57.1) 23 (65.7) 0.488
Classes of acute drugs
 NSAIDs, n (%) 12 (15.6) 8 (18.6) 4 (11.8) 0.809 7 (16.7) 5 (14.3) 0.457
 Triptans, n (%) 20 (26.0) 9 (20.9) 11 (32.4) 9 (21.4) 11 (31.4)
 Combination, n (%) 4 (5.2) 3 (7.0) 1 (2.9) 1 (2.4) 16 (45.7)
 Multiple drug classes, n (%) 41 (53.2) 23 (53.5) 18 (52.9) 25 (59.5) 3 (8.57)
Comorbidities
 Hypertension, n (%) 19 (24.7) 9 (20.9) 10 (29.4) 0.434 11 (26.2) 8 (22.9) 0.795
 Anxiety, n (%) 22 (28.6) 13 (30.2) 9 (26.5) 0.916 12 (28.6) 10 (28.6) 0.999
 Depression, n (%) 4 (5.2) 3 (7.0) 1 (2.9) 2 (4.8) 2 (5.7)
 Anxiety and depression, n (%) 18 (23.4) 9 (20.9) 9 (26.5) 10 (23.8) 8 (22.9)
 Insomnia, n (%) 33 (42.9) 18 (41.9) 15 (44.1) 0.842 18 (42.9) 15 (42.9) 1.000
Migraine features at baseline
 Monthly headache days (m ± sd) 24.6 ± 4.8 25.3 ± 4.2 23.7 ± 5.4 0.281 24.5 ± 4.4 23.7 ± 5.4 0.545
 Monthly migraine days (m ± sd) 23.0 ± 5.1 23.7 ± 4.8 22.0 ± 5.3 0.172 23.2 ± 4.5 22.0 ± 5.3 0.861
 Monthly days of acute drugs intake (m ± sd) 20.8 ± 7.6 22.8 ± 7.1 18.1 ± 7.5 0.005 21.5 ± 6.9 18.1 ± 7.5 0.534
 Monthly doses of acute drugs intake (m ± sd) 34.7 ± 29.9 39.9 ± 33.5 28.7 ± 23.5 0.045 33.4 ± 29.9 36.4 ± 31.6 0.662
Questionnaires at baseline
 MIDAS (m ± sd) 77.5 ± 69.0 80.9 ± 74.1 73.2 ± 62.6 0.275 72.1 ± 71.8 73.2 ± 62.8 0.452
 Mean headache intensity (m ± sd) 8.0 ± 6.4 7.3 ± 1.3 9.0 ± 9.4 0.461 7.3 ± 1.2 9.0 ± 9.4 0.349
 HIT-6 (m ± sd) 66.8 ± 5.8 67.1 ± 5.3 66.5 ± 6.4 0.651 65.8 ± 5.7 66.5 ± 6.5 0.113
 ASC-12 (allodynia) (m ± sd) 6.4 ± 5.1 5.9 ± 5.4 6.9 ± 4.8 0.264 6.2 ± 5.2 6.9 ± 4.8 0.707
 MSQ (m ± sd) 34.4 ± 18.1 38.1 ± 15.4 30.0 ± 20.3 0.068 37.4 ± 14.3 29.6 ± 20.3 0.190
 General Health (0–100) (m ± sd) 54.4 ± 22.3 54.2 ± 22.8 54.7 ± 21.9 0.869 61.5 ± 16.6 54.7 ± 22.0 0.002
 HADS-A (m ± sd) 6.51 ± 4.03 6.1 ± 3.7 7.0 ± 4.4 0.437 5.7 ± 3.6 7.0 ± 4.4 0.079
 HADS-D (m ± sd) 6.39 ± 4.40 6.0 ± 5.0 6.9 ± 4.3 0.255 5.4 ± 3.7 6.9 ± 4.3 0.035
  1. Legend: MIDASRes: Patients with a MIDAS score reduction of at least 50% at T3. NON-MIDASRes: Patients with a MIDAS score reduction < 50% at T3. MMDRes: Patients with a MMDs reduction of at least 50% at T3. NON-MMDRes: Patients with a MMDs reduction < 50% at T3. T3: follow-up visit at three months after first erenumab administration.
  2. CM Chronic migraine, CM + MOH Chronic migraine and medication overuse headache, BoNT-A Onabotulinumtoxin-A, MIDAS MIgraine Disability Assessment, HIT-6 Headache Impact Test-6, ASC-12 Allodynia Symptoms Checlist, MSQ Migraine-Specific Quality of Life Questionnaire, HADS Hospital Anxiety and Depression Scale. Data are presented as means ± standard deviations (m ± sd) or absolute values (percentages)